Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors

Quentin Giordan, Julia Salleron, Catherine Vallance, Clothilde Moriana and Christelle Clement-Duchene

1 Department of Pharmacy, Centre Hospitalier Régional de Metz-Thionville, Metz, France, 2 Biostatistics Unit, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France, 3 Department of Pharmacy, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France, 4 Department of Internal Medicine, Centre Hospitalier Régional Universitaire de Nancy, Vandœuvre-lès-Nancy, France, 5 Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France

Background: The use of antibiotics (ATB) and proton-pump inhibitors (PPI) alters the composition and diversity of the gut microbiota, which can influence the immune system, consequently interfering with response to anti-PD1 immune checkpoint inhibitors (ICI). We assessed the impact of ATB and/or PPI use on the efficacy and safety of ICI.

Methods: Two hundred twelve patients treated with anti-PD1 ICI for non-small cell lung carcinoma, melanoma, upper airway & digestive tract carcinoma or renal cell carcinoma were retrospectively included. Patients having received ATB within 60 days before ICI initiation were included in the ATB+ group. Patients having received PPI within 30 days before ICI initiation were included in the PPI+ group. Four groups were thus considered: ATB-/PPI-, ATB+/PPI-, ATB-/PPI+, ATB+/PPI+. Response rate was assessed by RECIST v1.1. Overall survival (OS), progression-free survival (PFS) and adverse events, recorded using Common Terminology Criteria for Adverse Events Version 5, were compared using inverse probability of treatment weighting to account for selection bias.

Results: PFS at 6 months was 56.7 %, 95%CI (49.6%; 63.2%) and 47.2 %, 95%CI (39.8%;54.1%) at 12 months. OS was 81.6%, 95%CI (75.6%; 86.2%) at 6 months, and 69.4%, 95%CI (61.9%;75.7%) at 12 months. Compared to ATB-/PPI- group, PFS was lower for the ATB+/PPI- group [Hazard ratio (HR) 1.90, 95%CI (1.41;2.57)] and the ATB-/ PPI+ group [HR 1.51, 95%CI (1.11;2.05)], and lowest in the ATB+/PPI+ group [HR 3.65, 95%CI (2.75;4.84)]. For OS, the use of ATB alone or PPI alone or in combination was a risk factor for death, with each increasing HR values by a similar magnitude, and the combination of ATB and PPI did not increase risk further. AEs were observed in 78 cases (36.8%) with no significant impact of ATB or PPI use.

Conclusions: This study reveals that ATB and/or PPI use can alter response to anti-PD1 ICI, and the prognosis of cancer patients. The microbiota mechanisms involved in the response to ICI should be investigated to optimize patient management.

Keywords: non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), melanoma, head and neck cancer, non-small-cell lung carcinoma (NSCLC), immune checkpoint inhibitors (ICI), antibiotics, proton-pump inhibitor (PPI)
INTRODUCTION

Since their introduction, immune checkpoint inhibitors (ICI) have considerably improved the management of patients with solid tumors, including non-small-cell lung carcinoma (NSCLC), melanoma, renal cell carcinoma (RCC) and cancers of the upper aerodigestive tract (UADT). By stimulating and reinforcing the immune system, ICIs act by blocking two cell checkpoints that help tumors to escape immune control, namely the programmed cell death 1 (PD-1) and programmed death-ligand 1 (PD-L1) (1) for pembrolizumab, nivolumab and atezolizumab, or the cytotoxic T-lymphocyte-associated protein 4 (2) for ipilimumab.

Recent systematic reviews have demonstrated the beneficial effects of ICIs on overall survival (OS) and progression-free survival (PFS) for first- (3) and second-line treatments (4) compared to chemotherapy in NSCLC patients. Long term survival has also been observed after treatment with ICIs for advanced melanoma (5) or RCC (6, 7). For patients with previously treated recurrent or metastatic UADT cancer, ICIs showed promising efficacy (8).

Recent studies have suggested that the use of antibiotics may be associated with worse outcomes in cancer patients treated with ICIs (9–12). Other studies have reported an impact of PPIs on the efficacy of ICIs (13, 14). However, the role of concomitant PPI use on the therapeutic efficacy of ICIs remains controversial, since it did not appear to be significantly associated with poorer prognosis in different cancer patients in a meta-analysis involving 1167 cancer patients from 5 studies (15). Finally, a drug-based prognostic score predicting OS, PFS and objective response rate (ORR) suggested that cumulative exposure to antibiotics and PPIs leads to progressively worse outcomes after ICI therapy (16).

The aim of our study was therefore to investigate the impact of ATB and PPI, either alone or in combination, on the efficacy and tolerance of ICI in patients with solid tumors in a real-world setting.

MATERIALS AND METHODS

Study Approval

In accordance with current French legislation, this study was declared to the French national data protection authority (Commission Nationale Informatique & Libertés). All patients were informed that their clinical data might potentially be used retrospectively for research purposes, and they were informed of their right to refuse this usage. No refusal was recorded. The scientific and ethical committee of the Institut de Cancérologie de Lorraine, Nancy, France, approved the study.

Data Collection

Using patients’ medical records, we retrospectively evaluated patient and tumor characteristics (gender, age, tumor location, histologic type, grade, PD-1 receptor and PD-L1 expression (percentage of tumor cells with positive membranous staining reported as the tumor proportion score), Eastern Cooperative Oncology Group Performance Status (PS), ICI use (start and end date, molecule used and treatment line, cause of treatment discontinuation), use of PPIs or ATBs (molecule and mode of administration, start and end date), appearance of immune-related AE (date, type, grade and location), PFS, OS and the best overall response to ICI.

Patient Selection

This was a single-centre, retrospective study. All consecutive patients with NSCLC, melanoma, RCC or UADT cancer who received at least one ICI injection from 1 January 2018 and 31 December 2019 were identified from the hospital informatics database. The ICI considered were nivolumab (associated or not with ipilimumab) and pembrolizumab. Inclusion criteria were as follows: Age ≥18 years old, World Health Organization performance status ≤2, immunotherapy according to the marketing authorization or expanded access status, use of anti PD-1/PD-L1 as monotherapy or combined with anti cytotoxic T-lymphocyte-associated protein. Exclusion criteria were systemic corticosteroid therapy using ≥10 mg daily dose of prednisone within 14 days prior to ICI initiation, or use of immunosuppressive agents within 14 days prior to immunotherapy, autoimmune disease or inflammatory bowel disease (IBD), and patients previously treated by ICI or receiving concomitant chemotherapy. Patients with atezolizumab were excluded due to the number of cases being too low for analysis as well as patients with UADT cancer treated in first or third line and more, melanoma treated in third line and more and RCC treated in first or third line and more.

Treatment and Assessment

Nivolumab was administered by intravenous infusion at a dose of 3 mg/kg every 2 weeks until August 2018 and thereafter, at a flat dose of 240mg every 2 weeks according to the recommended dosage change. In combination, patients received nivolumab at 1 mg/kg plus ipilimumab at 3 mg/kg every 3 weeks for 4 doses, followed by nivolumab at 3 mg/kg or at a flat dose of 240mg every 2 weeks. Pembrolizumab was administered at a dose of at a flat dose of 200mg every 3 weeks. Both drugs were administered until disease progression or onset of uncontrolable adverse events (AEs).

After the first ICI injection, patients were followed up every 12 weeks with medical imaging [thoraco-abdomino-pelvic computer tomography (CT) scan and brain magnetic resonance imaging (MRI)], and we recorded treatment response evaluated according to the Response Evaluation Criteria In Solid Tumors version 1.1. Prior to each ICI administration, patients were clinically assessed to identify AEs. Patients were followed up until death or data lock (31 May 2020).

The primary endpoint was progression free survival (PFS) defined as the time from immunotherapy initiation to progression or death. Efficacy was also assessed according to clinical response and OS. The best overall response rate was categorized as complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD). The ORR was
based on combining CR and PR, and the disease control rate (DCR) was based on combining CR, PR and SD response. OS was defined as the time from immunotherapy initiation to death, whatever the cause. Toxicity included both non-specific and autoimmune AEs. AEs were defined according to appearance and graded according to the Common Terminology Criteria for Adverse Events, version 5. The most severe AE from ICI initiation to the end of follow-up was considered. Only grade ≥2 AEs were considered.

**ATB and PPI Exposure**
Previous studies have shown that alteration of intestinal microbiota by ATB occurs within two months after ATB exposure (17, 18), while PPI treatment leads to dysbiosis after a continuous administration of 4 weeks (19). Consequently, patients who received ATB within a window of 60 days prior to ICI initiation were included in the ATB+ group, and patients who received PPIs within a window of 30 days prior to ICI initiation were included in the PPI+ group (19). Four groups were thus considered: ATB-/PPI-, ATB+/PPI-, ATB-/PPI+, ATB+/PPI+.

**Statistical Analysis**
Qualitative parameters are expressed as number and percentage. Quantitative parameters are expressed as means and standard deviation or median and interquartile range based on whether or not they had a normal distribution as assessed by the Shapiro-Wilk test.

The data comparison between the 4 groups was performed using the Chi-squared test or Fisher’s exact test for qualitative variables, and the Kruskal-Wallis test or analysis of variance (ANOVA) for quantitative parameters. For all further analyses, propensity score weighting was used to adjust the results for confounding factors by using the inverse probability of treatment weighting method (20). The propensity score was estimated using multinomial logistic regression using the groups as the dependent variable and PS, gender, age, grade and the interaction between tumour location and treatment line number as independent variables. Comparison of patient characteristics after weighting on the propensity score was performed, and results are expressed as hazard ratios and 95% confidence interval (95%CI). The details of antibiotic and PPI use are summarized in Tables 2, 3.

**Effect of ATB and PPI on Response to ICI**
Best overall response rates for each group are shown in Figure 2. The best response was achieved in 2.9 months [2.4; 5.3].

The ORR of the ATB-/PPI- group was higher than in patients treated with ATB and/or PPI (p=0.047). After weighting on propensity score, and compared to the ATB-/PPI- group, patients in the ATB-/PPI+ and ATB+/PPI+ groups had a lower probability of achieving objective response [odds ratio (OR) 0.60, 95%CI (0.40; 0.90) and OR 0.47, 95%CI (0.31; 0.72) respectively] (Table 4). There was no significant difference in ORR for the ATB+/PPI- compared to the ATB-/PPI- group [OR 0.81, 95%CI ([0.54; 1.22)]. Similarly, the DCR was also different according to ATB and/or PPI use (p<0.001), with a significantly lower probability of achieving disease control in the ATB+/PPI+ group (OR 0.20, 95%CI [0.13; 0.31]) compared to the ATB-/PPI-group (Table 4). There was no significant difference in DCR for the ATB+/PPI- [OR 0.74, 95%CI (0.49; 1.11)] and ATB-/PPI+ groups [OR 1.05, 95%CI (0.69; 1.58)]. The probability of achieving disease control was not significantly different according to prophylactic versus curative ATB (37.5% vs. 29.4%, p=0.518).

**RESULTS**

**Patient Characteristics**
From 1 January 2018 to 31 December 2019, 338 patients were prescribed ICI, of whom 212 were eligible and included in this analysis (Figure 1).

The population was composed of 143 men (67.5 %) and 69 women (32.5 %), and mean age was 63.9 ± 11.9 years. At ICI initiation, 187 patients (88.2 %) had a metastatic tumor, and 161 patients (76.3 %) had a PS ≤1. Fifty eight patients (27.2 %) received ATB within 60 days prior to ICI initiation. The median duration of antibiotic therapy was 14 days [8; 98] and was ≥7 days in 54 patients (93.1 %). Seventy-four patients (34.7 %) were treated with PPI during the month prior to ICI initiation. The median duration of treatment was 8.4 months (4.1; 14.8). No patients had intravenous PPI administration. Considering the combination of ATB and PPI use, 107 patients (50.5 %) had neither ATB nor PPI before ICI initiation (ATB-/PPI- group). While there were 31 patients (14.6 %) in the ATB+/PPI- group, 47 patients (22.2 %) in the ATB-/PPI+ group and 27 patients (12.7 %) in the ATB+/PPI+ group. As shown in Table 1, the demographic and baseline characteristics were balanced within groups, except for tumor location (p=0.001) and PS (p=0.001), with a Cramer’s V >0.3 corresponding to a moderate effect size. There was also a significant difference in the treatment line (p=0.002, Cramer’s V=0.26). After weighting on the propensity score, there were no longer any significant differences between groups, with all Cramer’s V close to 0.1, corresponding to a small effect size (see Additional file).

The best response was achieved in 2.9 months [2.4; 5.3].

The ORR of the ATB-/PPI- group was higher than in patients treated with ATB and/or PPI (p=0.047). After weighting on propensity score, and compared to the ATB-/PPI- group, patients in the ATB-/PPI+ and ATB+/PPI+ groups had a lower probability of achieving objective response [odds ratio (OR) 0.60, 95%CI (0.40; 0.90) and OR 0.47, 95%CI (0.31; 0.72) respectively] (Table 4). There was no significant difference in ORR for the ATB+/PPI- compared to the ATB-/PPI- group [OR 0.81, 95%CI ([0.54; 1.22)]. Similarly, the DCR was also different according to ATB and/or PPI use (p<0.001), with a significantly lower probability of achieving disease control in the ATB+/PPI+ group (OR 0.20, 95%CI [0.13; 0.31]) compared to the ATB-/PPI-group (Table 4). There was no significant difference in DCR for the ATB+/PPI- [OR 0.74, 95%CI (0.49; 1.11)] and ATB-/PPI+ groups [OR 1.05, 95%CI (0.69; 1.58)]. The probability of achieving disease control was not significantly different according to prophylactic versus curative ATB (37.5% vs. 29.4%, p=0.518).
Effect of ATB and PPI Use on PFS and OS

Median follow-up time was 10 months [interquartile range from 5 to 12 months]. PFS at 6 months was 56.7%, 95%CI (49.6%; 63.2%) and 47.2%, 95%CI (39.8%; 54.1%) at 12 months. Patients not treated with either ATB or PPI had better PFS than patients treated with ATB and/or PPI (p<0.001, Figure 3). After weighting on the propensity score, and compared to the ATB-/PPI- group, PFS was worse in the ATB+/PPI- [Hazard
TABLE 2 | Characteristics of antibiotic therapy for the 58 patients with ATB and according to PPI use.

| Antibiotics          | Total (n=58) | ATB+/PPI- (n=31) | ATB+/PPI+ (n=27) | p-value |
|----------------------|--------------|------------------|------------------|---------|
| Therapeutic class, n(%) |              |                  |                  |         |
| Beta lactams        | 32 (55.2)    | 17 (64.8)        | 15 (55.6)        | 0.956   |
| Fluoroquinolones    | 5 (8.6)      | 2 (6.5)          | 3 (11.1)         | 0.656   |
| Tetracyclines       | 18 (31.0)    | 11 (35.5)        | 7 (25.9)         | 0.433   |
| Other               | 9 (15.5)     | 3 (9.7)          | 6 (22.2)         | 0.279   |
| Prophylactic antibiotic treatment | |                  |                  |         |
| Indication, n(%)    |              |                  |                  |         |
| Lungs               | 15 (45.5)    | 5 (35.7)         | 10 (52.6)        | NC      |
| Cutaneous           | 12 (6.1)     | 1 (7.1)          | 1 (5.3)          |         |
| Urinary             | 5 (15.1)     | 2 (14.3)         | 3 (15.8)         |         |
| Septic              | 1 (3.0)      | 0                | 1 (5.3)          |         |
| Other               | 10 (30.3)    | 6 (42.9)         | 4 (21.0)         |         |

TABLE 3 | Characteristics of PPI use among the 74 patients with PPI and according to ATB use.

| PPI          | Total (n=74) | ATB-/PPI+ (n=47) | ATB+/PPI+ (n=27) | p-value |
|--------------|--------------|------------------|------------------|---------|
| Therapeutic class, n (%) |              |                  |                  |         |
| Pantoprazole | 31 (41.9)    | 19 (40.4)        | 12 (44.4)        | 0.085   |
| Esomeprazole | 17 (23.0)    | 12 (25.5)        | 5 (18.5)         |         |
| Lansoprazole | 11 (14.9)    | 8 (17.0)         | 3 (11.1)         |         |
| Rabeprazole  | 5 (6.8)      | 5 (10.6)         | 0 (0.0)          |         |
| Omeprazole   | 10 (13.5)    | 3 (6.4)          | 7 (25.9)         |         |
| Corticosteroid therapy, n (%) | 2 (2.7) | 2 (8.3) | 0 (0.0) | NC      |

ATB, Antibiotics; PPI, Proton-pump inhibitors; NC, not calculated.

Effect of ATB and PPI on AEs

Among the 212 patients, AEs were observed in 78 patients (36.8%). The median time to appearance of non-specific AEs was 28 days (15; 87) versus 84 days (42; 147) days for auto-immune AEs. No significant difference in the rate of AEs was observed between groups (p=0.58). The AEs are detailed by group in Table 5.

DISCUSSION

This study shows that PFS in patients not treated with either antibiotics or PPI prior to initiation of ICI treatment is superior to that of patients treated with ATB and/or PPI before ICIs. Moreover, the concomitant administration of ATB and PPI prior to ICI initiation may possibly be associated with a greater magnitude of negative effect on PFS. Regarding OS, ATB and PPI both exert a negative impact on OS, albeit without signs that the combination has an effect of increased magnitude. No significant impact of ATB or PPI use on ICI toxicity was observed.

Our findings are consistent with previous reports (9–12, 21, 22) indicating that the use of ATB is associated with poorer outcome and may influence the efficacy of ICI. As in recent studies (13, 14), we also found in multivariate analyses that PPI use increased the risk of progression and death, albeit less than twofold. Data on the concomitant use of PPI and ATB are sparse (14, 16) but are in line with our results. In our study, we show that the combination of ATB plus PPI, compared to either ATB or PPI alone, had a negative impact on PFS but not on OS. The significant results for PFS and not for OS could be explained by the fact that post-treatments can affect OS but also by a too short median follow-up time to assess the impact on OS.

The originality of our study in this regard is the inclusion of 4 groups of patients according to the use of PPI and/or ATB, and consequently, their synergistic effect, instead of considering PPI use as a patient characteristic (23). Chalabi et al (14) studied patients treated with atezolizumab, and showed that PPI use was associated with a greater risk of progression or death, while ATB use was associated with a greater risk of death. They also
TABLE 4 | Patient outcomes according to ATB and/or PPI use.

| Outcome   | ATB-/PPI- | ATB+/PPI- | ATB-/PPI+ | ATB+/PPI+ | P-value |
|-----------|-----------|-----------|-----------|-----------|---------|
| ORR       | Univariate analysis | n(%) | 47 (43.9%) | 8 (25.8%) | 13 (27.7%) | 6 (22.2%) | 0.047 |
|           | OR [95%CI] | Ref | 0.44 | [0.18;1.08] | 0.49 | [0.23;1.03] | 0.36 |
|           | Multivariate analysis* | OR [95%CI] | Ref | 0.81 | [0.54;1.22] | 0.60 | [0.40;0.90] | 0.47 |
| DCR       | Univariate analysis | n(%) | 72 (67.3%) | 13 (41.9%) | 25 (53.2%) | 6 (22.2%) | <0.001 |
|           | OR [95%CI] | Ref | 0.35 | [0.15;0.80] | 0.55 | [0.27;1.11] | 0.14 |
|           | Multivariate analysis* | OR [95%CI] | Ref | 0.74 | [0.49;1.11] | 1.05 | [0.69;1.58] | 0.20 |
| PFS       | Univariate analysis | At 6 months | 71.1% | 33.0% | 54.5% | 30.8% | <0.001 |
|           | HR [95%CI] | Ref | 3.39 | [1.98;5.85] | 2.23 | [1.33;3.73] | 4.82 |
|           | Multivariate analysis* | HR [95%CI] | Ref | 1.90 | [1.41;2.57] | 1.51 | [1.11;2.05] | 3.65 |
| OS        | Univariate analysis | At 6 months | 91.4% | 66.6% | 73.9% | 73.1% | 0.001 |
|           | HR [95%CI] | Ref | 2.68 | [1.22;5.92] | 3.17 | [1.64;6.11] | 3.24 |
|           | Multivariate analysis* | HR [95%CI] | Ref | 2.11 | [1.37;3.26] | 1.89 | [1.23;2.90] | 2.12 |

*After weighting on the propensity score. ATB, Antibiotics; PPI, Proton-pump inhibitors; ORR, objective response rate; DCR, disease control rate; PFS, Progression Free Survival; OS, Overall Survival; OR, Odds ratio; HR, Hazard ratio; CI, Confidence interval; Ref, Reference.
concluded that an effect of the concomitant use of ATB plus PPI could not be ruled out, since a deleterious effect of the combination was demonstrated in the atezolizumab group. Buti et al (16) developed a drug-based prognostic score ranging from 0 (best prognosis, the patient did not take any of corticosteroids, systemic antibiotics or PPIs) to 4 (worst prognosis, the patient was on treatment with corticosteroids, systemic antibiotics and PPIs at ICI initiation). They assigned 1 point for PPIs and 1 point for ATB, suggesting an additive effect, and demonstrated that the higher the score, the worse the PFS and OS. More recently, Cortellini et al. (24) showed that certain co-medications, including ATB and PPIs, had a negative impact on the efficacy of ICI in stage IV cancer patients. However, in this study, only prophylactic ATB decreased PFS and OS. In our study, the impact of prophylactic and curative ATB on efficacy was not significantly different and the therapeutic class of ATB could not be assessed due to the small sample size for each.

The reduced efficacy of ICI after ATB use may be related to gut dysbiosis. The administration of ATB could alter host microbiota symbiosis, with a decrease in the immunostimulatory function of the microbiota, leading to reduced efficacy of the ICI. Some commensal bacteria (Bifidobacterium) help antitumor immunity to develop, and enhance the intratumoral infiltration of dendritic cells and TH1 cells (25). The same was shown with Faecalibacterium, reported to increase PFS via the development of CD8+ cells in the tumor microenvironment (26). The abundance

**FIGURE 3** | Progression free survival according to ATB and/or PPI use. Significant differences after multivariate analysis are symbolized with a star.

**FIGURE 4** | Overall survival according to ATB and/or PPI use. Significant differences after multivariate analysis are symbolized with a star.
and diversity of the gut microbiota are also altered by the use of PPI. Various hypotheses can be put forward to explain this phenomenon. Firstly, the use of PPI may affect the abundance and diversity of *Bifidobacterium* and *Ruminococcaceae*, both indispensable to immunity (27, 28). Secondly, the use of PPI can affect immunity increasing the pH of the tumor microenvironment. In preclinical models, PPIs inhibit the vacuolar H+ATPase pump and reverse the pH gradient of an acidic TAM (29). In addition, the activation of PPIs would promote the recruitment of M2 subtype macrophages as well as the production of pro-inflammatory cytokines (interleukin 1, interleukin 7, nitric oxide, tumor necrosis factor alpha) (30). In this way, the immunosuppressive activity of the tumor microenvironment would be lost, and the activity of the ICI would be decreased.

Regarding ICI tolerance, no significant difference was observed for either non-specific (p=0.54) or autoimmune AEs (p=0.23), regardless of their grade. Our results are consistent with other studies (31, 32). In a preliminary study among patients with immune-related colitis treated with ICI prior to fecal microbiota transplantation (33), it was shown that fecal microbiota transplantation might alter the LyTCD8+/LyTreg immune balance, to the benefit of Treg Foxp3+ cell infiltration in the intestinal mucosa. Thus, an immunosuppressant and anti-inflammatory gut environment might help to control and reduce immune-related colitis. The *Bacteroidetes* phylum could play an immunomodulating role, enhancing the differentiation of naïve T cells into Treg cells, thus reducing colitis (34). It could thus be associated with improved autoimmune tolerance but decreased efficacy of ICIs. A prospective study of 26 patients with metastatic melanoma showed that the microbiota of responders to ICI was enriched with *Firmicutes*, in particular *Faecalibacterium prausnitzii* and *Gemmiger formicilis*. The butyrate-producing bacteria seem to decrease the efficacy of ICI and induced poorer tolerance to ICI due to the development of immune-related colitis (35).

This study has some limitations. Firstly, it was a retrospective and single-centre study. Moreover, as few patients presented AE, studies including larger sample sizes are needed to determine the

### TABLE 5 | Adverse events in the whole population and in each group.

|                | Total (n=212) | ATB-/PPI- (n=107) | ATB+/PPI- (n=31) | ATB-/PPI+ (n=47) | ATB+/PPI+ (n=27) | p-value |
|----------------|--------------|-------------------|------------------|------------------|------------------|---------|
| Adverse events, n(%) | 78 (36.8)    | 43 (40.2)         | 10 (32.3)        | 14 (29.8)        | 11 (40.8)        | 0.577   |
| ≥1 Non-specific events, n(%) | 59 (27.8)    | 30 (28.0)         | 9 (29.0)         | 10 (21.3)        | 10 (37.0)        | 0.538   |
| Grade, n(%)        |              |                   |                  |                  |                  |         |
| 2                | 50 (23.6)    | 27 (25.2)         | 6 (19.4)         | 8 (17.0)         | 9 (33.3)         |         |
| 3                | 9 (4.3)      | 3 (2.8)           | 3 (9.7)          | 2 (4.3)          | 1 (3.7)          |         |
| Asthenia, n(%)     |              |                   |                  |                  |                  |         |
| 2                | 35 (16.5)    | 15 (14.0)         | 4 (12.9)         | 7 (14.9)         | 9 (33.3)         |         |
| 3                | 7 (3.3)      | 2 (1.9)           | 3 (9.7)          | 1 (2.1)          | 1 (3.7)          |         |
| Cutaneous eruption, n(%) |            |                   |                  |                  |                  |         |
| 2                | 16 (7.6)     | 12 (11.2)         | 2 (6.5)          | 2 (4.3)          | 0 (0.0)          |         |
| 3                | 0 (0.0)      | 0 (0.0)           | 0 (0.0)          | 0 (0.0)          | 0 (0.0)          |         |
| Diarrhoea, n(%)   |              |                   |                  |                  |                  |         |
| 2                | 9 (4.3)      | 6 (5.6)           | 2 (6.5)          | 0 (0.0)          | 1 (3.7)          |         |
| 3                | 2 (0.9)      | 1 (0.9)           | 0 (0.0)          | 1 (2.1)          | 0 (0.0)          |         |
| ≥1 Auto-immune events, n(%) | 40 (18.9)    | 26 (24.3)         | 4 (12.9)         | 7 (14.9)         | 3 (11.1)         | 0.228   |
| Grade, n(%)       |              |                   |                  |                  |                  |         |
| 2                | 34 (16.0)    | 21 (19.6)         | 3 (9.7)          | 7 (14.9)         | 3 (11.1)         |         |
| 3                | 6 (2.8)      | 5 (4.7)           | 1 (3.2)          | 0 (0.0)          | 0 (0.0)          |         |
| Appearance, n(%)  |              |                   |                  |                  |                  |         |
| < 8 weeks         | 14 (35.0)    | 10 (38.5)         | 1 (25.0)         | 2 (28.6)         | 1 (33.3)         |         |
| ≥ 8 weeks         | 26 (65.0)    | 16 (61.5)         | 3 (75.0)         | 5 (71.4)         | 2 (66.7)         |         |
| Liver, n(%)       |              |                   |                  |                  |                  |         |
| 2                | 0 (0.0)      | 0 (0.0)           | 0 (0.0)          | 0 (0.0)          | 0 (0.0)          |         |
| 3                | 4 (1.9)      | 3 (2.8)           | 1 (3.2)          | 0 (0.0)          | 0 (0.0)          |         |
| Lung, n(%)        |              |                   |                  |                  |                  |         |
| 2                | 4 (1.9)      | 0 (0.0)           | 1 (3.2)          | 3 (6.4)          | 0 (0.0)          |         |
| 3                | 0 (0.0)      | 0 (0.0)           | 0 (0.0)          | 0 (0.0)          | 0 (0.0)          |         |
| Thyroid, n(%)     |              |                   |                  |                  |                  |         |
| 2                | 16 (7.6)     | 11 (10.3)         | 2 (6.5)          | 2 (4.3)          | 1 (3.7)          |         |
| 3                | 0 (0.0)      | 0 (0.0)           | 0 (0.0)          | 0 (0.0)          | 0 (0.0)          |         |
| Adrenal glands, n(%) |            |                   |                  |                  |                  |         |
| 2                | 11 (5.2)     | 9 (8.4)           | 1 (3.2)          | 1 (2.1)          | 0 (0.0)          |         |
| 3                | 0 (0.0)      | 0 (0.0)           | 0 (0.0)          | 0 (0.0)          | 0 (0.0)          |         |
| Colon, n(%)       |              |                   |                  |                  |                  |         |
| 2                | 6 (2.8)      | 4 (3.7)           | 0 (0.0)          | 1 (2.1)          | 1 (3.7)          |         |
| 3                | 1 (0.5)      | 1 (0.9)           | 0 (0.0)          | 0 (0.0)          | 0 (0.0)          |         |
| Other, n(%)       |              |                   |                  |                  |                  |         |
| 2                | 1 (0.5)      | 0 (0.0)           | 0 (0.0)          | 0 (0.0)          | 1 (3.7)          |         |
| 3                | 1 (0.5)      | 1 (0.9)           | 0 (0.0)          | 0 (0.0)          | 0 (0.0)          |         |

ATB, Antibiotics; PPI, Proton-pump inhibitors.
impact of ATB and/or PPI use on the occurrence of AEs. Certain parameters likely to modulate the diversity and composition of the microbiota were not recorded, such as diet or use of other drugs that could alter the microbiota. A high-fat diet rich in animal proteins increases biliary secretion and produces overexpression of the Bacteroides gene in order to convert these acids into short-chain fatty acids (36). Some treatments that were not considered in our study might also affect the microbiota, and could potentially interfere with immunity, such as second-generation antipsychotics (clozapine, olanzapine and risperidone), which are thought to cause dysbiosis, decreasing the abundance of *A. muciniphila* in the microbiota of non-obese patients (37), as well as non-steroidal anti-inflammatory drugs, which are thought to modulate interindividual diversity in the gut microbiome (16, 38).

The use of ATB and/or PPI affects response to ICIs and prognosis of patients with cancer. This study shows the impact of combined ATB/PPI therapy, which is often administered in cancer patients. However, further prospective studies with larger populations are essential to confirm these findings. Faecal analysis would also help to identify the commensal bacterial species that mediate patient prognosis. The modulation of microbiota could count among new therapeutic targets to ensure optimal management of patients treated with ICI.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**REFERENCES**

1. Cai J, Wang D, Zhang G, Guo X. The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy. *Onco Targets Ther* (2019) 12:437–45. doi: 10.2147/OTT.S221340
2. Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, et al. Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell Extrinsic Function of CTLA-4. *Science* (2011) 332(6029):600–3. doi: 10.1126/science.1202947
3. Chen R, Hou X, Yang L, Zhao D. Comparative Efficacy and Safety of First-Line Treatments for Advanced Non-Small Cell Lung Cancer With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. *Thorac Cancer* (2019) 10(4):607–23. doi: 10.1111/1759-7714.12971
4. Ramos-Esquivel A, van der Laat A, Rojas-Vigott R, Jua A. Antibiotics on the Clinical Outcomes of Patients With Solid Cancers Undergoing Immune Checkpoint Inhibitor Treatment: A Retrospective Study. *BMC Cancer* (2020) 31(4):525. doi: 10.1186/s12885-020-07214-4
5. Yu H, Xu X, Wang H, Ge W, Cao D. The Association Between Antibiotics Use and Outcome of Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. *Crit Rev Oncol Hematol* (2020) 149:102909. doi: 10.1016/j.critrevonc.2020.102909
6. Yang M, Wang Y, Yuan M, Tao M, Kong C, Li H, et al. Antibiotic Administration Shortly Before or After Immunotherapy Initiation Is Correlated With Poor Prognosis in Solid Cancer Patients: An Up-to-Date Systematic Review and Meta-Analysis. *Int Immunopharmacol* (2020) 88:106876. doi: 10.1016/j.intimp.2020.106876
7. Kim H, Kwon M, Kim B, Jung HA, Sun JM, Lee SH, et al. Clinical Outcomes of Immune Checkpoint Inhibitors for Patients With Recurrent or Metastatic Head and Neck Cancer: Real-World Data in Korea. *BMC Cancer* (2020) 20(1):727. doi: 10.1186/s12885-020-07214-4
8. Kim H, Lee JE, Hong SH, Lee MA, Kang JH, Kim I-H. The Effect of Antibiotics on the Clinical Outcomes of Patients With Solid Cancers Undergoing Immune Checkpoint Inhibitor Treatment: A Retrospective Study. *BMC Cancer* (2019) 19(1):1100. doi: 10.1186/s12885-019-6267-z
9. Homicsko K, Richtig G, Tuchmann Z, Hanahan D, Coukos G, et al. Proton Pump Inhibitors Negatively Impact Survival of PD-1 Inhibitor Based Therapies in Metastatic Melanoma Patients. *Ann Oncol* (2018) 29(10):2391–400. doi: 10.1093/annonc/mdy311
10. Homicsko K, Richtig G, Tuchmann Z, Hanahan D, Coukos G, et al. Proton Pump Inhibitors Negatively Impact Survival of PD-1 Inhibitor Based Therapies in Metastatic Melanoma Patients. *Ann Oncol* (2018) 29(10):2391–400. doi: 10.1093/annonc/mdy311
11. Homicsko K, Richtig G, Tuchmann Z, Hanahan D, Coukos G, et al. Proton Pump Inhibitors Negatively Impact Survival of PD-1 Inhibitor Based Therapies in Metastatic Melanoma Patients. *Ann Oncol* (2018) 29(10):2391–400. doi: 10.1093/annonc/mdy311
12. Homicsko K, Richtig G, Tuchmann Z, Hanahan D, Coukos G, et al. Proton Pump Inhibitors Negatively Impact Survival of PD-1 Inhibitor Based Therapies in Metastatic Melanoma Patients. *Ann Oncol* (2018) 29(10):2391–400. doi: 10.1093/annonc/mdy311
13. Homicsko K, Richtig G, Tuchmann Z, Hanahan D, Coukos G, et al. Proton Pump Inhibitors Negatively Impact Survival of PD-1 Inhibitor Based Therapies in Metastatic Melanoma Patients. *Ann Oncol* (2018) 29(10):2391–400. doi: 10.1093/annonc/mdy311
14. Homicsko K, Richtig G, Tuchmann Z, Hanahan D, Coukos G, et al. Proton Pump Inhibitors Negatively Impact Survival of PD-1 Inhibitor Based Therapies in Metastatic Melanoma Patients. *Ann Oncol* (2018) 29(10):2391–400. doi: 10.1093/annonc/mdy311

**ETHICS STATEMENT**

Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. The ethics committee waived the requirement of written informed consent for participation.

**AUTHOR CONTRIBUTIONS**

CV and CC-D designed and directed the project. QG and JS interpreted the patient data. JS performed statistical analyses. QG and JS wrote the manuscript. All authors contributed to the article and approved the submitted version.

**ACKNOWLEDGMENTS**

We thank Victorien Attenot and Fiona Ecault, PhD (EA3920, University of Franche-Comté) for editorial assistance and review.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.716317/full#supplementary-material
15. Li C, Xia Z, Li A, Meng J. The Effect of Proton Pump Inhibitor Uses on Outcomes for Cancer Patients Treated With Immune Checkpoint Inhibitors: A Meta-Analysis. Ann Transl Med (2020) 8(24):1655. doi: 10.21037/atm-20-7498

16. Buti S, Bersanelli M, Perrone F, Tiseo M, Tucci M, Adamo V, et al. Effect of Concomitant Medications With Immune-Modulatory Properties on the Outcomes of Patients With Advanced Cancer Treated With Immune Checkpoint Inhibitors: Development and Validation of a Novel Prognostic Index. Eur J Cancer (2021) 142:18–28. doi: 10.1016/j.ejca.2020.09.033

17. Jakobsson HE, Jernberg C, Andersson AF, Sjölund-Karlsson M, Jansson JK, Engstrand L. Short-Term Antibiotic Treatment has Differing Long-Term Impacts on the Human Throat and Gut Microbiome. Philos One (2010) 5(3): e9836. doi: 10.1371/journal.pone.0009836

18. Lange K, Buerger M, Stallmach A, Bruns T. Effects of Antibiotics on Gut Microbiota. DDI (2016) 34(3):260–8. doi: 10.1159/000443360

19. Jackson MA, Goodrich JK, Maxan ME, Freedberg DE, Abrams JA, Poole AC, et al. Proton Pump Inhibitors Alter the Composition of the Gut Microbiota. Gut (2016) 65(5):749–56. doi: 10.1136/gutjnl-2015-310861

20. Rosenbaum PR. Optimal Matching for Observational Studies. J Am Stat Assoc (1989) 84(408):1024–32. doi: 10.1080/01621459.1989.10478686

21. Elkrief A, Derosa L, Kroemer G, Zitvogel L, Routy B. The Negative Impact of Antibiotics on Outcomes in Cancer Patients Treated With Immunotherapy: A New Independent Prognostic Factor? Ann Oncol (2019) 30(10):1572–9. doi: 10.1093/annonc/mdz206

22. Derosa L, Hellmann MD, Spiaziano M, Halpenny D, Fidelde M, Rizvi H, et al. Negative Association of Antibiotics on Clinical Activity of Immune Checkpoint Inhibitors in Patients With Advanced Renal Cell and Non-Small-Cell Lung Cancer. Ann Oncol (2018) 29(6):1437–44. doi: 10.1093/annonc/mdy103

23. Ahmed J, Kumar A, Parikh K, Anwar A, Knoll BM, Puccio C, et al. Use of Broad-Spectrum Antibiotics Impacts Outcome in Patients Treated With Immune Checkpoint Inhibitors. Oncimmuneology (2018) 7(11):e1507670. doi: 10.1002/1622402X.2018.1507670

24. Cortellini A, Tucci M, Adamo V, Stucci LS, Russo A, Tanda ET, et al. Integrated Analysis of Concomitant Medications and Oncological Outcomes From PD-1/PD-L1 Checkpoint Inhibitors in Clinical Practice. J Immunother Cancer (2020) 8(2):e001361. doi: 10.1136/jitc-2020-001361

25. Vézizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, et al. Anticancer Immunotherapy by CTLA-4 Blockade Relies on the Gut Microbiota. Science (2015) 350(6264):1079–84. doi: 10.1126/science.aad1139

26. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karnetls TV, et al. Gut Microbiome Modulates Response to Anti–PD-1 Immunotherapy in Melanoma Patients. Science (2018) 359(6371):97–103. doi: 10.1126/science.aaw4236

27. Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, et al. Gut Microbiome Influences Efficacy of PD-1–Based Immunotherapy Against Epithelial Tumors. Science (2018) 359(6371):91–7. doi: 10.1126/science.aan3706

28. Imhann F, Bonder MJ, Vich Vila A, Fu J, Mujagic Z, Vork L, et al. Proton Pump Inhibitors Affect the Gut Microbiome. Gut (2016) 65(5):740–8. doi: 10.1136/gutjnl-2015-310376

29. Bellone M, Calcinotto A, Filippazzi P, Milito AD, Fais S, Rivoltini L. The Acidity of the Tumor Microenvironment Is a Mechanism of Immune Escape That can be Overcome by Proton Pump Inhibitors. OncoImmunology (2013) 2(1):e22058. doi: 10.4161/onci.22058

30. Vishvakarma NK, Singh SM. Immunopotentiating Effect of Proton Pump Inhibitor Pantoprazole in a Lymphoma-Bearing Murine Host: Implication in Antitumor Activation of Tumor-Associated Macrophages. Immunol Letters (2010) 134(1):83–92. doi: 10.1016/j.imlet.2010.09.002

31. Zhao S, Gao G, Li W, Li X, Zhao C, Jiang T, et al. Antibiotics Are Associated With Attenuated Efficacy of Anti-PD-1/PD-L1 Therapies in Chinese Patients With Advanced Non-Small Cell Lung Cancer. Lung Cancer (2019) 130:10–7. doi: 10.1016/j.lungcan.2019.01.017

32. Huemer F, Rinnerthaler G, Westphal H, Hutaure G, Ganpmreiender SP, et al. Impact of Antibiotic Treatment on Immune-Checkpoint Blockade Efficacy in Advanced Non-Squamous non-Small Cell Lung Cancer. Oncotarget (2018) 9(23):16512–20. doi: 10.18632/oncotarget.24751

33. Wang Y, Wiesnski DH, Helmkir BA, Gopalakrishnan V, Choi K, DuPont HL, et al. Fecal Microbiota Transplantation for Refractory Immune Checkpoint Inhibitor-Associated Colitis. Nat Med (2018) 24(12):1804–8. doi: 10.1038/s41591-018-0238-9

34. Dubin K, Callahan MK, Ren B, Khanin R, Viale A, Ling L, et al. Intestinal Microbiome Analyses Identify Melanoma Patients at Risk for Checkpoint-Blockade-Induced Colitis. Nat Commun (2016) 7(1):10391. doi: 10.1038/ncomms10391

35. Chaput N, Lepage P, Coutaz C, Soulard E, Le Roux K, Monot C, et al. Baseline Gut Microbiota Predicts Clinical Response and Colitis in Metastatic Melanoma Patients Treated With Ipilimumab. Ann Oncol (2017) 28(6):1368–79. doi: 10.1093/annonc/mdx108

36. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, et al. Diet Rapidly and Reproducibly Alters the Human Gut Microbiome. Nature (2014) 505(7484):559–63. doi: 10.1038/nature12820

37. Flowers SA, Evans SJ, Ward KM, McInnis MG, Ellingrod VL. Interaction Between Atypical Antipsychotics and the Gut Microbiome in a Bipolar Disease Cohort. Pharmacotherapy (2017) 37(3):261–7. doi: 10.1002/phar.1890

38. Rogers MAM, Aronoff DM. The Influence of Nonsteroidal Anti-Inflammatory Drugs on the Gut Microbiome. Clin Microbiol Infect (2016) 22(2):178.e1–9. doi: 10.1016/j.cmi.2015.10.003

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Giordan, Salleron, Vallance, Moriana and Clement-Duchene. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.